SMT201300106B - Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo - Google Patents

Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo

Info

Publication number
SMT201300106B
SMT201300106B SM201300106T SM201300106T SMT201300106B SM T201300106 B SMT201300106 B SM T201300106B SM 201300106 T SM201300106 T SM 201300106T SM 201300106 T SM201300106 T SM 201300106T SM T201300106 B SMT201300106 B SM T201300106B
Authority
SM
San Marino
Prior art keywords
amorphous
sulfonamido
alpha
acetamide compound
bioavailable compositions
Prior art date
Application number
SM201300106T
Other languages
English (en)
Italian (it)
Inventor
Ruiling F Hartley
Raja M Haddadin
Feng Qian
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT201300106B publication Critical patent/SMT201300106B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM201300106T 2009-04-14 2013-09-24 Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo SMT201300106B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906609P 2009-04-14 2009-04-14
PCT/US2010/030679 WO2010120662A2 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
SMT201300106B true SMT201300106B (it) 2013-11-08

Family

ID=42664672

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300106T SMT201300106B (it) 2009-04-14 2013-09-24 Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo

Country Status (21)

Country Link
US (1) US20100261768A1 (xx)
EP (1) EP2419086B1 (xx)
JP (1) JP2012524090A (xx)
KR (1) KR20120027142A (xx)
CN (1) CN102387788B (xx)
AR (1) AR076306A1 (xx)
AU (1) AU2010236701A1 (xx)
BR (1) BRPI1012523A2 (xx)
CA (1) CA2758709A1 (xx)
DK (1) DK2419086T3 (xx)
EA (1) EA201171207A1 (xx)
ES (1) ES2426403T3 (xx)
HR (1) HRP20130807T1 (xx)
MX (1) MX2011010513A (xx)
NZ (1) NZ595411A (xx)
PL (1) PL2419086T3 (xx)
PT (1) PT2419086E (xx)
SI (1) SI2419086T1 (xx)
SM (1) SMT201300106B (xx)
TW (1) TW201043269A (xx)
WO (1) WO2010120662A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162498A0 (en) 2001-12-20 2005-11-20 Bristol Myers Squibb Co (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US9095585B2 (en) * 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999007A (en) * 1975-10-09 1976-12-21 Carl Joseph Crane Aircraft visual approach/landing reproducer device and system
US5136301A (en) * 1989-08-30 1992-08-04 Rockwell International Corporation Primary flight display system having a vertical linear altimeter
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
EP0750238B1 (en) * 1995-06-20 2000-03-01 Honeywell Inc. Integrated ground collision avoidance system
IL123901A (en) * 1995-11-17 2003-06-24 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them
US6233522B1 (en) * 1998-07-06 2001-05-15 Alliedsignal Inc. Aircraft position validation using radar and digital terrain elevation database
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6570531B1 (en) * 2000-04-27 2003-05-27 Rockwell Collins, Inc. Satellite navigation receiver designed for compatibility with aircraft automatic landing systems
US6483454B1 (en) * 2000-11-28 2002-11-19 Bae Systems Aerospace Inc. Close formation aircraft collision avoidance
IL162498A0 (en) * 2001-12-20 2005-11-20 Bristol Myers Squibb Co (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
TWI336698B (en) * 2003-03-31 2011-02-01 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
FR2870605B1 (fr) * 2004-05-18 2010-10-08 Airbus France Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude
FR2880456B1 (fr) * 2005-01-03 2007-02-23 Airbus France Sas Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef
FR2886439B1 (fr) * 2005-05-24 2010-11-05 Eurocopter France Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude
KR101374928B1 (ko) * 2005-11-09 2014-03-14 노파르티스 아게 일시적 가소제를 사용한 약학 조성물의 제조 방법
FR2897448B1 (fr) * 2006-02-14 2008-03-14 Airbus France Sas Procede et systeme d'aide au pilotage d'un aeronef.
KR20080093126A (ko) * 2006-02-17 2008-10-20 와이어쓰 술폰아미드 치환된 알코올 및 이의 중간체의 제조 방법
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
RS20090406A (xx) * 2006-03-20 2010-12-31 Vertex Pharmaceuticals Incorporated Farmaceutske smeše
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
FR2911988B1 (fr) * 2007-01-26 2016-03-25 Airbus France Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
TW201043269A (en) 2010-12-16
DK2419086T3 (da) 2013-09-30
JP2012524090A (ja) 2012-10-11
SI2419086T1 (sl) 2013-10-30
MX2011010513A (es) 2011-11-29
CN102387788A (zh) 2012-03-21
PL2419086T3 (pl) 2013-11-29
EP2419086A2 (en) 2012-02-22
AR076306A1 (es) 2011-06-01
AU2010236701A1 (en) 2011-10-20
CN102387788B (zh) 2013-07-10
EP2419086B1 (en) 2013-06-26
WO2010120662A3 (en) 2011-09-15
ES2426403T3 (es) 2013-10-23
NZ595411A (en) 2013-02-22
WO2010120662A2 (en) 2010-10-21
EA201171207A1 (ru) 2012-03-30
CA2758709A1 (en) 2010-10-21
US20100261768A1 (en) 2010-10-14
PT2419086E (pt) 2013-09-04
HRP20130807T1 (hr) 2013-09-30
BRPI1012523A2 (pt) 2016-03-29
KR20120027142A (ko) 2012-03-21

Similar Documents

Publication Publication Date Title
SMT201300106B (it) Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
SI2576523T1 (sl) Kristalinične oblike 4-(5-(3-kloro-5-(trifluorometil)fenil)-4,5-dihidro 5-(trifluorometil)-3-izoksazolil)-N-(2-okso-2-((2,2,2-trifluoroetil) amino)etil)-1 naftalenkarboksamida
DK1874306T3 (da) Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
WO2006100635A3 (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NL1029799A1 (nl) Enantiomeer zuivere aminoheteroarylverbindingen als proteïnekinaseremmers.
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20083630L (no) Nye pyridinderivater
NO20071593L (no) Pyrimidinderivater
NO20090628L (no) Pyridizinon derivativater
MY154909A (en) Novel thiophene derivatives
DK1957656T3 (da) Fermentativ fremstilling af lysin
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
DK2147098T3 (da) Anvendelse af proteinhydrolysater til stabilisering af metalloprotease-detergent-formuleringer
NO20091395L (no) Nye tiofenderivater
MX2011010514A (es) Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida.
DK1954241T3 (da) Zonisamid-formulering med vedvarende frigivelse
DK2073805T3 (da) Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
WO2010055119A3 (en) Pharmaceutical composition comprising pimobendan
DK1809253T3 (da) Stabiliseret frysetørret formulering til cephalosporinderivater
IL184558A0 (en) Sustained release composition of protein drug
NI201000052A (es) Composición de zibotentan que contiene manitol y/o celulosa microcristalina.
WO2007025774A3 (en) Cysteine protease inhibitors